A Phase 2b Proof-of-Concept Study of CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC)
Latest Information Update: 09 Feb 2025
Price :
$35 *
At a glance
- Drugs CNP 104 (Primary)
- Indications Primary biliary cirrhosis
- Focus Adverse reactions
- 04 Feb 2025 According to Cour Pharmaceutical Development media release, the Phase 2b in Primary Biliary Cholangitis (PBC) trial is expected to begin this year.
- 24 Dec 2021 New trial record